

# Company Highlights

- Offering a generic pharmaceutical product portfolio of over 190 NDC's spanning 60 product families
- Dosage forms available include oral solids, liquids, injectables, and topicals
- Wockhardt USA LLC represents 20% of Wockhardt's global business
- Sales growth of 140% for 2008 versus 2007
- Twenty products launched in 2008 and 2009
- Azithromycin Tabs, Phenytoin Sodium ER Caps, Ropinirole Tabs, Midazolam inj, Granisetron inj, Risperidone Tabs launched in 2008. Divalproex ER Tabs, Risperidone OS, Ranitidine OS, Nicardipine Inj. and Sumatriptan vials launched in 2009, Tamsulosin Tablets in 2010
- 10 product launches planned for 2010
- Over 50 ANDA's pending approval from the FDA
- 12 FDA approved manufacturing facilities worldwide producing APIs, Steriles, Orals, Topicals, and Liquids allowing vertical product integration
- Vertical integration of products via our manufacturing plants in the US, Europe and India

